Dataset related to article "Soluble PD-L1 in NSCLC Patients Treated With Checkpoint Inhibitors and Its Correlation With Metabolic Parameters"

This record contains raw data related to article “Soluble PD-L1 in NSCLC Patients Treated With Checkpoint Inhibitors and Its Correlation With Metabolic Parameters" Abstract We investigated the role of soluble PD-L1 (sPD-L1) in non-small cell lung carcinoma (NSCLC) patients treated with immune checkpoint inhibitors (ICI) and analyzed its association with clinical outcomes and metabolic parameters by 18F-fluorodeoxyglucose positron emission tomography/computed tomography (18F-FDG-PET/CT). Between July 2017 and May 2019, we enrolled 20 candidate patients of ICI therapy who had serum frozen samples and 18F-FDG PET/CT available, both at baseline and at the first response evaluation. This analysis is embedded into a larger prospective study (NCT03563482). Twelve out of 20 patients received nivolumab, one patient received combination of nivolumab and ipilimumab, whereas the others received pembrolizumab. Median sPD-L1 level at baseline was 27.22 pg/mL. We found a significant association between patients with elevated sPD-L1, above the median value, and high metabolic tumor burden, expressed by metabolic tumor volume (MTV, 115.3 vs. 35.5, <em>p</em> = 0.034) and total lesion glycolysis (TLG, 687 vs. 210.1, <em>p</em> = 0.049). At the first restaging after 7-8 weeks, median sPD-L1 levels significantly increased as compared to baseline median value (43.9 pg/mL, <em>p</em> = 0.017). No significant differences in response rates were detected, according to both morphological and metabolic response criteria. Likewise, no difference in survival outcomes were observed between low sPD-L1 and high sPD-L1 patients. The increase of sPD-L1 concentrations during ICI treatment may reflect the expansion of tumor volume and the tumor lysis. Moreover, it is supposed that sPD-L1 has its own biological action, either by reducing membrane PD-1 sites available for nivolumab or by inducing lymphocytes exhaustion after binding their membrane PD-1. Further, larger studies are needed to confirm our preliminary results on the role of sPD-L1 during ICI therapy.本数据集包含与论文"Soluble PD-L1 in NSCLC Patients Treated With Checkpoint Inhibitors and Its Correlation With Metabolic Parameters"相关的原始数据。【摘要】本研究探讨了可溶性PD-L1（soluble PD-L1, sPD-L1）在接受免疫检查点抑制剂（immune checkpoint inhibitors, ICI）治疗的非小细胞肺癌（non-small cell lung carcinoma, NSCLC）患者中的作用，并通过18F-氟脱氧葡萄糖正电子发射断层扫描/计算机断层扫描（18F-fluorodeoxyglucose positron emission tomography/computed tomography, 18F-FDG-PET/CT）分析了其与临床结局及代谢参数的相关性。2017年7月至2019年5月期间，本研究纳入20例接受ICI治疗的候选患者，所有患者均留存基线期及首次疗效评估阶段的冷冻血清样本与18F-FDG-PET/CT影像资料。本分析隶属于一项更大规模的前瞻性研究（NCT03563482）。20例患者中，12例接受纳武利尤单抗（nivolumab）单药治疗，1例接受纳武利尤单抗联合伊匹木单抗（ipilimumab）治疗，其余患者接受帕博利珠单抗（pembrolizumab）治疗。患者基线期的sPD-L1中位水平为27.22 pg/mL。本研究发现，基线sPD-L1水平高于中位值的患者，其代谢肿瘤负荷更高，该结果通过代谢肿瘤体积（metabolic tumor volume, MTV：115.3 vs. 35.5，*p*=0.034）与总病灶糖酵解（total lesion glycolysis, TLG：687 vs. 210.1，*p*=0.049）得以体现，组间差异具有统计学意义。在治疗7~8周后的首次分期复查中，患者的sPD-L1中位水平较基线期显著升高（43.9 pg/mL，*p*=0.017）。无论采用形态学还是代谢疗效评估标准，均未检测到客观缓解率存在显著差异；同样，sPD-L1高水平与低水平患者的生存结局亦无显著差异。ICI治疗期间sPD-L1浓度升高，可能反映肿瘤体积增大及肿瘤溶解现象。此外，有假说认为sPD-L1可独立发挥生物学功能：一方面可减少可结合纳武利尤单抗的细胞膜PD-1位点，另一方面可在结合细胞膜PD-1后诱导淋巴细胞耗竭。未来需开展更大规模的研究，以验证本研究关于sPD-L1在ICI治疗中作用的初步结果。